Pilocarpine Hydrochloride Ophthalmic Solution 0.4%

Introduction Overview

Generic Name

pilocarpine hydrochloride ophthalmic solution 0.4%

Brand Name

Qlosi

Dosage Form

eye drop (ophthalmic solution)

Drug Class

cholinergic agonist (miotic agent)

Pharmacokinetics

Absorption: Pilocarpine hydrochloride ophthalmic solution is administered topically to the eye, resulting in rapid local absorption through the corneal epithelium. Because of its direct ocular application, systemic absorption is minimal but can occur via conjunctival vessels and nasolacrimal drainage into the nasal mucosa. The onset of action of Qlosi is observed approximately 20 minutes post-instillation, corresponding to its ocular absorption and receptor interaction time frame. Systemic bioavailability is limited, which reduces the potential for systemic side effects.

Distribution: After ocular absorption, pilocarpine mainly acts locally on muscarinic receptors in the eye, particularly the iris sphincter muscle and ciliary body. Target tissue distribution is confined to the anterior chamber structures to exert miotic and accommodation effects necessary for presbyopia treatment. Minimal systemic distribution occurs due to the small doses administered via eye drops, and pilocarpine does not significantly cross the blood-brain barrier or accumulate in systemic tissues under normal therapeutic dosing conditions.

Metabolism: Pilocarpine undergoes minimal metabolism at therapeutic doses following ophthalmic use. Systemically absorbed pilocarpine is primarily metabolized hepatically by plasma cholinesterases and hepatic enzymes; however, the exact metabolic pathways have not been exhaustively characterized for eye drop formulations. The inactive metabolites are subsequently eliminated via renal excretion.

Elimination: Systemically absorbed pilocarpine has a relatively short half-life ranging from approximately 0.76 to 1.3 hours when administered systemically, but systemic levels after topical ophthalmic administration remain low. The primary route of elimination of the drug and its metabolites is renal. Due to the topical ocular route, the drug’s local ocular effects persist up to about 8 hours, corresponding more to receptor binding and physiological response rather than systemic pharmacokinetics. Ophthalmic drops are typically washed away by tears and nasolacrimal drainage, limiting prolonged ocular exposure beyond intended dosing times.

Dosage Forms

Available Dosage Forms: Qlosi is formulated as a sterile, preservative-free ophthalmic solution at a concentration of 0.4% pilocarpine hydrochloride. It is supplied in single-patient-use vials containing 0.4 mL of solution each. The vials are presented in protective foil pouches, with the following packaging: 5 single-use vials per pouch, box of 10 vials (2 pouches), and box of 20 vials (4 pouches).

Dosages for Adults and Adolescents: For adults with presbyopia, the recommended dosage is one drop instilled in each eye up to twice daily. If a second dose is required, it may be administered 2 to 3 hours after the first drop. The accommodative and miotic effect can last up to 8 hours. The drug is intended for on-demand use or daily administration, depending on individual patient needs and response.

Specific Patient Populations: Use in pediatrics has not been established; Qlosi is indicated for adults with presbyopia. Patients with a history of retinal detachment, iritis, or ocular inflammation should use Qlosi cautiously, and it is contraindicated in those with hypersensitivity to pilocarpine or formulation excipients. Special considerations include removing contact lenses prior to administration and waiting 10 minutes before reinsertion. Also, patients should be counseled about potential visual side effects, particularly with night driving or operating machinery.

Mechanism Of Action

Qlosi’s active ingredient, pilocarpine hydrochloride, is a cholinergic agonist that selectively stimulates muscarinic receptors, predominantly the M3 subtype, located on the smooth muscles of the iris sphincter and ciliary body. By binding to these receptors, pilocarpine induces contraction of the iris sphincter muscle, resulting in miosis (pupillary constriction). A smaller pupil size increases the depth of focus and reduces spherical aberrations, which is particularly beneficial in improving near vision in patients with presbyopia.

Additionally, pilocarpine causes contraction of the ciliary muscle, thereby enhancing the eye's accommodative ability. This contraction facilitates the lens to increase its curvature, enabling better focusing on near objects, which naturally declines in presbyopic patients due to lens stiffening and reduced flexibility with age. This dual effect on pupil size and accommodation is central to Qlosi's therapeutic action.

Pharmacodynamically, Qlosi's low concentration (0.4%) allows for a balance between efficacy in improving near vision and minimizing adverse effects, such as excessive miosis or accommodative spasm, which can impair distance vision. The preservation-free formulation supports tolerability by reducing ocular surface irritation. Clinical studies (NEAR-1 and NEAR-2) demonstrated that Qlosi significantly improves near visual acuity by three or more lines without compromising distance vision.

Compared to other miotic agents, pilocarpine’s ocular effects are well-characterized and relatively short-acting, allowing flexible dosing regimens. Unlike anticholinergic agents that dilate the pupil, pilocarpine’s stimulation of parasympathetic pathways directly targets ocular muscles responsible for accommodation and pupil size modulation, offering a unique advantage in presbyopia management. Research continues to explore optimization of dosing and formulations to enhance patient outcomes.

Pharmacological Actions

Acts as a muscarinic cholinergic receptor agonist stimulating M3 receptors on iris sphincter and ciliary muscles.
Induces pupillary constriction (miosis), decreasing pupil size to improve depth of field and near vision clarity.
Stimulates contraction of ciliary muscle to enhance accommodation capability of the eye lens.
Increases aqueous humor outflow via the trabecular meshwork, though this effect is less relevant at low doses for presbyopia.
Produces reversible changes in ocular muscle tone, facilitating transient improvements in near vision.
Exerts local pharmacological effects primarily on anterior segment ocular structures with minimal systemic absorption.
Preservative-free formulation reduces ocular surface irritation and hypersensitivity potential.
Pharmacodynamic effects begin within 20 minutes and can last up to 8 hours per dose.
Provides an alternative to external corrective lenses for managing presbyopia.
Minimal systemic anticholinergic or parasympathomimetic side effects at therapeutic ophthalmic doses.

Therapeutic Or Clinical Uses

Treatment of presbyopia in adults to improve near visual acuity without compromising distance vision.
Non-invasive alternative to reading glasses or contact lenses specifically for age-related near vision decline.
On-demand use or scheduled daily administration for patients requiring periodic near focus correction.
Management of visual activities requiring enhanced near focus such as reading, computer use, or detailed craftsmanship.
Potential utility in patients seeking a pharmacologic approach to overcome accommodative deficits due to lens hardening.
Adjunctive therapy in presbyopic patients to improve quality of life and reduce dependence on optical devices.
Use in individuals contraindicated or unwilling to use multifocal contact lenses or surgical interventions.
Treatment supported by FDA approval after demonstrating efficacy and safety in phase 3 clinical trials.
Improvement in near vision measurable within 20 minutes of instillation.
Maintenance of distance vision acuity during therapy without clinically significant deterioration.

Side Or Adverse Effects

Painful or sore eyes occurring in 5% to 8% of patients, generally mild and transient.
Headache reported in a similar percentage of patients (5-8%), usually resolving without intervention.
Blurred vision observed in 2% to 5% of users, typically short-lived and dose-related.
Local ocular irritation, including itching or discomfort upon instillation.
Rare risk of retinal detachment, necessitating retinal examination prior to therapy initiation.
Potential for induced iritis or exacerbation of existing ocular inflammation.
Transient reduction in night vision due to pupillary constriction affecting scotopic vision.
Hypersensitivity reactions such as allergic conjunctivitis or eyelid edema in sensitive individuals.
Occasional tearing or lacrimation immediately following drop administration.
Discomfort related to contact lens removal and reinsertion timings if not properly followed.
Possible ocular surface dryness or mild corneal irritation with repeated application.
No significant systemic side effects reported at ophthalmic dosing; systemic anticholinergic effects unlikely.
Potential for decreased distance vision if dosing or concentration exceeds recommended levels.
Very rare severe hypersensitivity or anaphylactic reactions, considering the localized topical route.

Precautions

Perform retinal evaluation before initiating therapy due to risk of retinal detachment.
Caution in patients with active or history of iritis or other intraocular inflammations.
Avoid driving or operating heavy machinery if experiencing blurred vision post-instillation.
Remove contact lenses prior to administration and delay reinsertion by at least 10 minutes.
Use cautiously in patients with known hypersensitivity to pilocarpine or any formulation excipients.
Avoid touching tip of single-use vial to eye or any surface to prevent contamination and eye injury.
Administer multiple topical ocular medications at least 5 minutes apart to avoid dilution or interactions.
Monitor for signs of ocular irritation or allergic reactions throughout therapy.
Consider careful use in patients with narrow anterior chamber angles or risk of angle-closure glaucoma.
Pregnancy and breastfeeding considerations: discuss risks and benefits with healthcare provider due to limited data.
Patients with impaired pupillary response may require close monitoring for adverse effects.
Store vials refrigerated until opened; follow storage instructions to preserve drug integrity.
Educate patients on proper instillation techniques and disposal of single-use vials after each application.

Warnings

Avoid driving or operating machinery if experiencing blurred vision after instillation.
There is a rare but serious risk of retinal detachment associated with miotic agents like pilocarpine; retinal evaluation is recommended before use.
Use with caution in patients with a history of iritis or ocular inflammation to prevent exacerbation.
Discard single-patient-use vials immediately after use to prevent contamination and infection.
Avoid use in patients with known allergy to pilocarpine hydrochloride or any inactive ingredients.
Be cautious with use during activities requiring sharp visual acuity or in dim lighting conditions due to pupillary constriction.
Potential transient decrease in distance vision may affect certain activities; patients should be warned.
Do not exceed recommended twice-daily dosing to reduce risk of adverse effects.
Avoid use in patients with narrow-angle glaucoma without appropriate ophthalmic assessment.
Immediate medical attention should be sought if patients experience sudden onset of flashes, floaters, or vision loss.
Pregnancy category not well established; use only if benefits outweigh potential risks.
Topical administration reduces systemic exposure but monitor for rare systemic cholinergic effects.

Contraindication

Known hypersensitivity or allergy to pilocarpine hydrochloride or any component of Qlosi formulation.
Patients with active ocular infections or severe eye inflammation at the time of treatment initiation.
Individuals with a history of retinal detachment or retinal tears without recent ophthalmic clearance.
Patients with narrow angle glaucoma not adequately managed or assessed by an ophthalmologist.
Not indicated for use in pediatric populations; safety and efficacy not established in children.
Contraindicated in those with hypersensitivity to preservatives or other ophthalmic solutions mistakenly added (Qlosi is preservative-free but cross-reactivity with other agents possible).
Avoid if patient demonstrates hypersensitivity to other cholinergic agonist medications.
Do not use simultaneously with indwelling intraocular foreign bodies due to potential irritation.

Drug Interactions

Concurrent use with other miotic agents may potentiate excessive pupillary constriction and ocular side effects.
Use with anticholinergic agents such as atropine may antagonize pilocarpine’s effects reducing efficacy.
Coadministration with other topical ocular drugs (e.g., beta-blockers, prostaglandin analogues) requires a 5 minute interval to avoid dilution.
Systemic cholinergic or anticholinergic drugs may influence ocular response; monitor for altered efficacy or side effects.
Use caution with other drugs that affect intraocular pressure to avoid adverse additive effects.
No significant systemic metabolic drug interactions due to minimal systemic absorption.
Caution advised when used with systemic drugs affecting parasympathetic nervous system due to additive effects.
Interactions with contact lens solutions are minimal, but lens removal is recommended during administration to prevent incompatibility.
Patients using monoamine oxidase inhibitors (MAOIs) or other CNS active agents may experience altered pupillary responses.
No known clinically significant pharmacokinetic interactions with common systemic medications.

Preparations Of The Drug

Qlosi is supplied as a sterile, preservative-free ophthalmic solution containing pilocarpine hydrochloride 0.4% (4 mg/mL).
Available in single-patient-use vials containing 0.4 mL solution each to prevent contamination and improve safety.
Packaged in foil pouches containing 5 single-use vials each providing protection from light and moisture.
Commercial packaging includes boxes of 10 vials (2 pouches) and boxes of 20 vials (4 pouches) for patient convenience.
Formulation includes inactive ingredients such as hypromellose, sodium chloride, sodium hyaluronate, edetate disodium dihydrate, and water for injection.
May contain sodium hydroxide and/or hydrochloric acid for pH adjustment ensuring optimal ocular tolerability.
No antimicrobial preservatives included to minimize ocular surface irritation and hypersensitivity reactions.
Refrigerated storage recommended at 2°C to 8°C (36°F to 46°F) to maintain drug stability.
Once pouch is opened, vials may be stored at room temperature up to 25°C (77°F) and used within 30 days.
Single-use vial design facilitates precise dosing and reduces risk of contamination or dosing errors.
Prescribing information and patient instructions highlight proper instillation techniques and vial disposal after use.
Manufactured for Orasis Pharmaceuticals, Ltd., ensuring industry standards for sterile ophthalmic preparations.